Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study

BACKGROUND: This study was to investigate the effects and safety of cathepsin B-cleavable doxorubicin (DOX)-prodrug (PDOX) for targeting therapy of metastatic human hepatocellular carcinoma (HCC) using DOX as a positive control drug. METHODS: The orthotopic nude mice model of highly metastatic HCC w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wang, Qun, Zhong, Yan-Jun, Yuan, Jing-Ping, Shao, Li-Hua, Zhang, Jue, Tang, Li, Liu, Shao-Ping, Hong, Ya-Ping, Firestone, Raymond A, Li, Yan
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3765954/
https://ncbi.nlm.nih.gov/pubmed/23961994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-192
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars